Today: 9 April 2026
India stock market today: Nifty, Sensex slip in late trade as Reliance drops, tariff jitters linger

India stock market today: Nifty, Sensex slip in late trade as Reliance drops, tariff jitters linger

Mumbai, January 6, 2026, 15:20 IST — Regular session

Indian equities were lower in late afternoon trade on Tuesday, with heavyweight stocks keeping benchmarks under pressure. The Nifty 50 was down 0.34% at 26,159.90 and the Sensex was off 0.47% at 85,037.57 at 3:02 p.m. IST, with decliners outnumbering advancers.

The pullback follows a rally that took the Nifty to an intraday record of 26,373.20 on Monday before it reversed to close 0.30% lower at 26,250.3, while the Sensex ended down 0.38%. Trade worries sharpened after U.S. President Donald Trump said tariffs on India could be raised if New Delhi does not curb purchases of Russian oil, on top of existing U.S. tariffs of up to 50%, while IT shares slid ahead of quarterly results due from next week. Reuters

HDFC Bank’s provisional December-quarter update has also kept attention on deposit mobilisation, a key driver of loan growth. “Given the current deposit mobilisation trends, we believe there is a downside risk to our deposit growth estimates,” analysts at Macquarie said. Reuters

On Tuesday, Reliance Industries and HDFC Bank led the drag among blue-chips in early trade, down 3% and 1.6%. Reliance said it “does not expect any Russian crude deliveries in January,” and “sentiment remains subdued due to geopolitical tensions and … trade frictions,” said Ajit Mishra, senior vice president of research at Religare Broking.

Stock-specific moves were sharp. Trent fell 7.5% after its business update, Tata Motors Passenger Vehicles slid after its unit JLR flagged a 43.3% drop in third-quarter volumes following a cyber incident, while Kotak Mahindra Bank and Axis Bank rose after upbeat updates and Emmvee Photovoltaic Power jumped after Jefferies initiated coverage with a “buy” rating.

Energy names were a key weak spot, with the Nifty Oil & Gas index down 2.07% at 11,962.20 at 2:16 p.m. after hitting its lowest since Dec. 30; BPCL and HPCL were among the laggards. Globe Capital Markets flagged a near-term “support” zone — a level where buyers often step in — around 11,750–11,690 for the sector gauge. Business Standard

In currency markets, the rupee firmed after state-run banks sold dollars, touching 90.0900 per dollar from Monday’s close of 90.2750, though traders said importers used the bounce to hedge, or lock in future exchange rates. “The decent dips (on dollar/rupee) are still used to hedge … that behaviour hasn’t really changed,” a banker said. Reuters

Domestic data offered a mixed cue on demand. A survey showed services growth cooled to an 11-month low in December, with the HSBC India Services PMI easing to 58.0 from 59.8, while staying comfortably above the 50 mark that separates expansion from contraction. Reuters

The risk is that tariff rhetoric hardens into policy or oil volatility pushes inflation expectations higher, making investors less tolerant of expensive pockets of the market. Earnings misses, especially in sectors with large U.S. exposure such as IT services, would add to the pressure.

Traders are now watching for fresh tariff headlines and Friday’s U.S. employment report for December 2025, due at 8:30 a.m. ET, for clues on the global rate path and risk appetite.

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:16 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
New Zealand Stock Market Ends Higher as BlueScope Bid Sparks Steel Rally, Infratil Gains
Previous Story

New Zealand Stock Market Ends Higher as BlueScope Bid Sparks Steel Rally, Infratil Gains

UK stock market today: FTSE 100 hits fresh high as Next upgrade lifts retailers and oil majors rise
Next Story

UK stock market today: FTSE 100 hits fresh high as Next upgrade lifts retailers and oil majors rise

Go toTop